PubMed Health⌕ Search

Biomedical subjects

James Leggett

Publications and source records attributed to James Leggett.

2 recordsLinked to original sources

Hemispherical gradient coils for magnetic resonance imaging.

Hemispherical gradient coils offer an open geometry that is well suited to imaging of the human brain. The windings of a hemispherical gradient coil are on average closer to the target region than those of a comparable cylindrical coil, and consequently hemispherical coils can produce higher efficiency at fixed inductance. The mathematical formalism needed for the design of hemispherical gradient coils is described here, including expressions relating the current distribution on the hemisphere to the magnetic field generated, as well as the stored energy and power dissipation. In addition, expressions for the torque experienced by the current distribution in the presence of the main magnetic field have been derived and used to develop an approach allowing the design of torque-balanced, hemispherical transverse gradient coils. Hemispherical coil designs suitable for brain imaging are presented and shown to have improved performance compared with their cylindrical counterparts. Small, prototype, hemispherical z- and x-gradient coils have been constructed and tested in phase-mapping experiments at 3 T. The experimental results show good agreement with theoretical predictions, validating the mathematical expressions used in the coil design process. The formalism also allows the design of coils wound on a complete spherical surface, and the performance of such coils is additionally described here.

Brain Mapping↗

Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.

Gatifloxacin, gemifloxacin, and moxifloxacin are the newest fluoroquinolones and show excellent in vitro activity against a wide variety of respiratory tract pathogens, many gram-negative aerobic organisms, and Bacteroides fragilis. These agents may be administered as oral and/or intravenous formulations with excellent bioavailability. The pharmacodynamics of these 3 new fluoroquinolones is more favorable than that of levofloxacin or ciprofloxacin for Streptococcus pneumoniae. All 3 agents are approved for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia. In addition, gatifloxacin and moxifloxacin are approved for the treatment of sinusitis. The toxicity of these 3 agents appears to be similar to that of the other fluoroquinolones in terms of gastrointestinal and central nervous system disturbances. All 3 agents have a low risk of phototoxicity, but gemifloxacin is associated with an increased risk of skin rash that is not a photoreaction. These agents can be useful for treatment of bacterial respiratory tract infections in patients who are allergic to beta-lactams, but caution must be exercised to avoid the potential for selection of widespread resistance, which may occur with indiscriminate use.

Aza Compounds↗